Gilead Seeks To Limit Sovaldi/Harvoni Royalties In Wake Of Merck's Patent Victory
This article was originally published in The Pink Sheet Daily
Executive Summary
As jury hears arguments on damages, Gilead asks court to find Merck was dishonest in obtaining its hepatitis C treatment patents and tries to quash a pricing argument; Merck wants 10% of future sales.